Tenderwize
Wróć do wyszukiwania

Non-exclusive agreement for fremanezumab medicines

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Mar 31, 2028 · 582 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Fremanezumab (ATC-Code: N02CD03) im Wege eines Open-House-Modells

52/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

52 / 100

Złożoność

58 / 100

Czynniki ryzyka

The exact submission instructions and all deadlines are said to be contained in project-room documents that were not pr...

Only pharmaceutical undertakings within the meaning of section 4(18) AMG may participate, and local representatives qua...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Supply of pharmaceutical products containing the active substance fremanezumab (ATC code N02CD03).
  • Open-House participation model for non-exclusive contractual arrangements.
Pokaż pełne podsumowanie

This is an Open-House supply arrangement for pharmaceutical products containing fremanezumab (ATC N02CD03), led by AOK PLUS. It is non-exclusive, open to all interested pharmaceutical companies that meet and accept the participation conditions. No individual negotiations or guaranteed minimum purchase volumes are provided. Participation documents must be obtained via DTVP after access approval, and participation requests are submitted electronically through the portal communication function. The arrangement runs until 31 March 2028 at the latest. The notice contains several technical/formal fields that are stated to have no substantive legal meaning for this Open-House procedure.

Ryzyka

The exact submission instructions and all deadlines are said to be contained in project-room documents that were not pr...

Only pharmaceutical undertakings within the meaning of section 4(18) AMG may participate, and local representatives qua...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of the notice.

Eligibility

  • The declaration on non-existence of exclusion grounds must be completed and submitted.

Administrative

  • Participation conditions in the documents must be accepted.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive agreement for fremanezumab medicines

Open-House supply arrangement for medicines containing fremanezumab (ATC N02CD03). The lot is described as a non-exclusive agreement open to all interested pharmaceutical companies that satisfy the participation conditions. No minimum purchase quantity is guaranteed and demand is stated to be unknown. Place of performance is Dresden, Germany, with broader reference to Germany / Saxony / Thuringia in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Mar 2026 - Mar 2028

Kategoria

Pharmaceutical products

Termin

Deadline Mar 31, 2028

Szczegóły zamówienia

Data publikacji
05 Feb 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
88189-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3